Emgality ® ▼ (galcanezumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Emgality Summary of Product Characteristics (SmPC)

Emgality® ▼ (galcanezumab): Use of Concomitant Medications in Phase 3 Migraine Prevention Studies

Certain concomitant medications were allowed in clinical trials, including some with specific restrictions.

Description of Analysis

Galcanezumab has been studied in phase 3, randomized, double-blind, placebo-controlled studies in adult patients for the prevention of

  • episodic migraine (EVOLVE-1 and EVOLVE-2)1,2

  • chronic migraine (REGAIN),3 and

  • episodic or chronic migraine that has not benefited from 2 to 4 previous migraine prevention medication categories (CONQUER).4

Concomitant Medications in Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies for Migraine Prevention

As shown in Appendix Concomitant Medications and Therapies Allowed and Not Allowed in the Phase 3 Migraine Prevention Studies, medications or classes of medications, herbal remedies, and physical treatments (such as electrical stimulation or physical therapy on the head or neck area) with potential for impact on migraine headache outcome were disallowed.5 Otherwise, concomitant medications without potential impact on migraine were permitted although some required stabilization prior to study entry in order to decrease potential confounding factors. Patients with prior exposure to therapeutic antibodies were excluded.5

Medications Allowed for the Acute Treatment of Migraine Headaches or Other Pain or Injury

Medications allowed for the acute treatment of migraine headaches or other pain or injury during phase 3 migraine prevention studies included1-5

  • acetaminophen (paracetamol)

  • NSAIDs

  • triptans

  • ergotamine and derivatives

  • isometheptene mucate

  • dichloralphenazone and acetaminophen combination (Midrin), or

  • combinations thereof.1,4,5

Medications allowed with restrictions included

  • opioid and barbiturates no more than 3 days/month in the EVOLVE-1, EVOLVE-2, and REGAIN studies

  • opioid and barbiturates no more than 4 days/month in the CONQUER study, and

  • single dose of injectable steroids only once during the study in an emergency setting.1-5

Medications Allowed for Migraine Prevention

In general, migraine preventive treatments were not allowed at any time in the EVOLVE-1, EVOLVE-2, and CONQUER studies from the start of the prospective lead-in phase through the end of the double-blind treatment period.1,2,4,5

However, in the chronic migraine prevention study (REGAIN), up to 1/3 of enrolled patients were allowed to continue migraine prophylactic treatment with either topiramate or propranolol if

  • the patient had been on a stable dose for at least 2 months prior to baseline, and

  • dosing remained stable throughout the double-blind treatment period.3,5

Patients discontinued botulinum toxin A or B in the head or neck area at least

  • 4 months prior to baseline in the EVOLVE studies and REGAIN,1-3,5 and

  • 3 months prior to baseline in the CONQUER study.4

Most Frequently Used Concomitant Medications (≥5%) During Double-Blind Treatment

The most frequently used concomitant medications during double-blind treatment recorded by patients are listed in Table 1.5 Across the migraine prevention studies, 79.6% to 92.8% used a concomitant therapy during the study. In the open-label treatment phase of the REGAIN study, 87.4% of patients used a concomitant therapy. There were statistically significant differences between treatment groups in the use of some concomitant medications; however, none of the differences were believed to be clinically meaningful or have an impact on study outcomes.

Table 1. Most Frequently Used Concomitant Medications (≥5%) During Double-Blind Treatment in Migraine Prevention Trials5

Concomitant Medicationa

EVOLVE-1 (N=858)

EVOLVE-2 (N=915)

REGAIN (N=1113)

CONQUER (N=462)

Ibuprofen

35.6%

30.2%

23.6%

6.9%

Paracetamol (acetaminophen)

21.8%

19.6%

16.1%

9.1%

Thomapyrin N

19.9%

10.6%

8.5%

NA

Sumatriptan

14.7%

12.2%

12.0%

NA

Vitamins not otherwise specified

13.3%

5.8%

6.1%

NA

Naproxen

8.2%

5.7%

6.6%

NA

Vitamin D not otherwise specified

8.2%

N/A

NA

NA

Naproxen sodium

7.9%

5.7%

5.8%

NA

Cetirizine hydrochloride

7.1%

6.9%

NA

NA

Salbutamol (albuterol)

5.8%

NA

NA

NA

Diphenhydramine hydrochloride

5.8%

NA

NA

NA

Loratadine

5.2%

NA

NA

NA

Acetylsalicylic acid

NA

6.9%

5.7%

NA

Ketorolac

NA

5.7%

NA

NA

Levothyroxine sodium/levothyroxine

NA

5.8%

NA

9.5%

Topiramate

NA

NA

10.3%

NA

Omeprazole

NA

NA

5.8%

6.7%

Levonorgestrel

NA

NA

NA

5.2%

Abbreviations: eCRF = electronic case report form; ePRO = electronic patient-reported outcomes; NA = not applicable.

a In the EVOLVE-1, EVOLVE-2, and REGAIN studies, concomitant medication use was recorded using the ePRO diary. In the CONQUER study, concomitant medication use was recorded using a general concomitant medication eCRF.

Therapeutic Indication

The recommended dose is 120 mg galcanezumab injected subcutaneously once monthly, with a 240 mg loading dose as the initial dose.6

Galcanezumab is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.6

References

1. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080-1088. http://dx.doi.org/10.1001/jamaneurol.2018.1212

2. Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454. http://dx.doi.org/10.1177/0333102418779543

3. Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-e2221. http://dx.doi.org/10.1212/WNL.0000000000006640

4. Mulleners WM, Kim BK, Láinez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19(10):814-825. http://dx.doi.org/10.1016/S1474-4422(20)30279-9

5. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

6. Emgality [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Glossary

eCRF = electronic case report form

NSAID = nonsteroidal anti-inflammatory drug

Appendix

Concomitant Medications and Therapies Allowed and Not Allowed in the Phase 3 Migraine Prevention Studies

Table 2. Treatments Allowed and Treatments Not Allowed as Concomitant Therapy During the Treatment Phase in Galcanezumab Phase 3, Double-Blind, Placebo-Controlled Migraine Prevention Studies5

Allowed (Restrictions Noted)

Not Allowed for any Reason or Indication

Acetaminophen (paracetamol)

NSAIDs

Triptans

Ergotamine and derivatives

Isometheptene mucate, dichloralphenazone and acetaminophen combination, or combinations thereofa

Acetazolamide

Acupuncture

Anticonvulsants/Antiepilepticsb

Antipsychotics

Beta-blockersc

Botulinum toxin applied to head/neck area

Cannabis/Cannabinoids

Chiropractic procedures, physiotherapy, TENS or other electric devices on head and neck

Corticosteroids for oral use

Flunarizine

Gabapentind

Herbals with anti-inflammatory effect (feverfew, willow bark, and petasites/butterbur), herbals with sympathomimetic effect (ma-huang, ephedra, bitter orange, and synephrine) and herbals with catecholamine transmitter reuptake inhibition (St. John’s Wort)e

MAOIs

Memantine

Methysergidef

Neurotropin®f

Nerve block in the head/neck areaf

Oxetoronef

Pizotifenf

Pregabalind

Serotonin 5HT2a/2c antagonists, eg, trazodone, nefazodone

Stimulants (prescription strength), eg, methylphenidate, dextroamphetamine, mixed amphetamine salts

Tizanidine

Therapeutic antibodiesgh

TCAs

Triptans for prevention of menstrual-related migraine

Venlafaxine

Verapamil

Opioid and barbituratesi

Single dose of injectable steroidsj

ACE inhibitors
ARBs
Benzodiazepines
Bupropion
Calcium-channel blockers (except verapamil and flunarizine)k
Clonidine
Guanfacine
Mirtazapine
SSRIs/NRIs/SNRIs (other than venlafaxine)
Use of electric devices (ie, TENS), physiotherapy, chiropractic procedures on low back and extremitiesl

 

Beta-blockers, ophthalmic
Cyclandelate
Cyproheptadine
Melatoninm

Abbreviations: ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; CGRP = calcitonin gene-related peptide; 5HT2a/2c = 5-hydroxytryptamine subtype 2a/2c; MAOI = monoamine oxidase inhibitor; NRI = norepinephrine reuptake inhibitor; NSAIDs = nonsteroidal anti-inflammatory drugs; SNRI = serotonin norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; TENS = transcutaneous electrical nerve stimulation.

a Medications allowed for the acute treatment of migraine headaches or other pain or injury.

b In the REGAIN study, up to 1/3 of enrolled patients were allowed to continue migraine prophylactic treatment with topiramate if the patient had been on a stable dose for at least 2 months prior to baseline, and dosing remained stable throughout the double-blind treatment period.

c In the REGAIN study, up to 1/3 of enrolled patients were allowed to continue migraine prophylactic treatment with propranolol if the patient had been on a stable dose for at least 2 months prior to baseline, and dosing remained stable throughout the double-blind treatment period.

d Explicitly disallowed only in the CONQUER study. However, all studies generally disallowed the use of antiepileptic medications for any reason.

e Only herbals with anti-inflammatory effects were disallowed in the CONQUER study.

f Only disallowed in the CONQUER study.

g Examples of therapeutic antibodies include adalimumab, infliximab, trastuzumab, and bevacizumab. Patients who are taking, or are expected to take, therapeutic antibodies during the course of the study were excluded from the EVOLVE-1, EVOLVE-2, and REGAIN studies. Patients who have previously completed or were withdrawn from studies investigating galcanezumab or other CGRP antibodies were excluded from all studies.

h Prior use of therapeutic antibodies, other than antibodies to CGRP or its receptor, is allowed if that use was more than 12 months prior to the prospective baseline period in the EVOLVE-1, EVOLVE-2, and REGAIN studies.

i Allowed for the acute treatment of migraine headaches or other pain or injury, no more than 3 days/month from prospective baseline period through double-blind treatment period in the EVOLVE-1, EVOLVE-2, and REGAIN studies; included the open-label extension phase in the REGAIN and CONQUER studies. In the CONQUER study, the restriction was no more than 4 days/month.

j Allowed only once during the study for the acute treatment of migraine headaches or other pain or injury, in an emergency setting from prospective baseline period through double-blind treatment period; included the open-label extension phase in the REGAIN and CONQUER studies.

k The CONQUER study also disallowed the use of lomerizine.

l Restricted use from the prospective baseline through double-blind treatment periods: use of these medications for indications other than migraine prevention is allowed providing the dose is stable 2 months prior to entering the prospective baseline period and is expected to remain stable from the start of the prospective baseline period through the end of the double-blind treatment period.

m Restricted medication during the prospective baseline and double-blind treatment periods in the EVOLVE-1, EVOLVE-2, and REGAIN studies. Use of these medications for indications other than migraine prevention was allowed.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: November 17, 2020


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request